Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Adi Treasurywala is active.

Publication


Featured researches published by Adi Treasurywala.


Biochemical Pharmacology | 1996

In vitro characterization of a novel series of platelet-derived growth factor receptor tyrosine kinase inhibitors

David G. Sawutz; Donald C. Bode; G.Maurice Briggs; John Reid; Paul C. Canniff; Lisa Caldwell; Connie R. Faltynek; Deborah Miller; Joseph A. Dunn; Lawrence de Garavilla; Joseph Guiles; Carolyn Weigelt; William F. Michne; Adi Treasurywala; Paul J. Silver

In this report, we describe the discovery and characterization of a novel biarylhydrazone series of platelet-derived growth factor (PDGF) receptor tyrosine kinase inhibitors typified by the prototype WIN 41662 (3-phenyl-N1-[1-(4-pytidyl)pyrimidine]hydrazone). WIN 41662 inhibited PDGF-stimulated autophosphorylation of PDGF receptors from human vascular smooth muscle cells (hVSMC) with an IC50 value of 60 nM. The inhibitor appeared to be competitive with respect to substrate (Mn(2+)-ATP), having a calculated Ki of 15 +/- 5 nM. WIN 41662 was approximately 500-fold more potent in inhibiting the PDGF receptor tyrosine kinase than the p56lck tyrosine kinase. It was inactive against other serine/threonine and tyrosine kinases tested. WIN 41662 produced concentration-dependent inhibition of PDGF-stimulated receptor autophosphorylation in intact hVSMC with an IC50 < 100 nM. Intracellular Ca2+ mobilization and cell proliferation were events that occurred in hVSMC subsequent to PDGF receptor activation. WIN 41662 inhibited PDGF-stimulated Ca2+ mobilization and cell proliferation ([3H]TdR incorporation) with IC50 values of 430 nM and 2.3 microM, respectively. These effects appeared to be specifically related to PDGF receptor tyrosine kinase inhibition since WIN 41662 was not cytotoxic (in vitro) and since WIN 72039, a close structural analog that does not inhibit PDGF receptor tyrosine kinase, also did not inhibit PDGF-stimulated receptor autophosphorylation, Ca2+ mobilization, or hVSMC proliferation. Thus, WIN 41662 is representative of a novel class of selective PDGF receptor tyrosine kinase inhibitors that inhibit PDGF-regulated secondary events in intact cells.


Tetrahedron Letters | 1995

A theoretical investigation of the N-oxide moiety

Robert B. Perni; Paul Kowalczyk; Adi Treasurywala; Michael Tracy

Abstract Molecular orbital calculations were carried out for pyridine-1-oxide and to determine the level of theory required to accurately represent the NO bond. The results clearly show that semi-empirical calculations fail to reproduce experimental values for bond lengths in pyridine-1-oxide. Lower level ab initio basis sets also provided poor results. STO-6-31G ∗∗ does, however provide good agreement with experiment for the NO bond lengths of pyridine-1-oxide.


Journal of Virology | 1989

Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors.

Daniel C. Pevear; M J Fancher; Peter J. Felock; Michael G. Rossmann; M S Miller; Guy D. Diana; Adi Treasurywala; Mark A. McKinlay; Frank J. Dutko


Journal of Medicinal Chemistry | 1984

N-[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]- N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor.

Kazimir Sestanj; Francesco Bellini; Steven Fung; Nedumparambil Abraham Abraham; Adi Treasurywala; Leslie G. Humber; N. Simard-Duquesne; D. Dvornik


Archive | 1981

N-naphthoylglycine derivatives

Kazimir Sestanj; Nedumparambil Abraham Abraham; Francesco Bellini; Adi Treasurywala


Journal of Medicinal Chemistry | 1995

Novel Inhibitors of Potassium Ion Channels on Human T Lymphocytes

William F. Michne; Joseph Guiles; Adi Treasurywala; Laurie A. Castonguay; Carolyn Weigelt; Bernard O'Connor; Walter A. Volberg; Alison M. Grant; Christopher C. Chadwick; Douglas S. Krafte; Roger J. Hill


Journal of Medicinal Chemistry | 1992

CoMFA analysis of the interactions of antipicornavirus compounds in the binding pocket of human rhinovirus-14

Guy D. Diana; Paul Kowalczyk; Adi Treasurywala; Richard C. Oglesby; Daniel C. Pevear; Frank J. Dutko


Journal of Medicinal Chemistry | 1990

A model for compounds active against human rhinovirus-14 based on X-ray crystallography data.

Guy D. Diana; Adi Treasurywala; Thomas R. Bailey; Richard C. Oglesby; Daniel C. Pevear; Frank J. Dutko


Journal of Medicinal Chemistry | 1988

Enantiomeric effects of homologues of disoxaril on the inhibitory activity against human rhinovirus-14

Guy D. Diana; Michael J. Otto; Adi Treasurywala; Mark A. McKinlay; Richard C. Oglesby; Edward G. Maliski; Michael G. Rossmann; Thomas J. Smith


Journal of Medicinal Chemistry | 1989

Computer assisted design and synthesis of novel aldose reductase inhibitors

John A. Butera; Jehan F. Bagli; Wendel Doubleday; Leslie G. Humber; Adi Treasurywala; Deborah A. Loughney; Kazimir Sestanj; Jane Millen; Janet Sredy

Collaboration


Dive into the Adi Treasurywala's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Guy D. Diana

Rensselaer Polytechnic Institute

View shared research outputs
Top Co-Authors

Avatar

Frank J. Dutko

Rensselaer Polytechnic Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Paul Kowalczyk

Rensselaer Polytechnic Institute

View shared research outputs
Top Co-Authors

Avatar

Carolyn Weigelt

Rensselaer Polytechnic Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Joseph Guiles

Colorado State University

View shared research outputs
Top Co-Authors

Avatar

Mark A. McKinlay

Rensselaer Polytechnic Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge